ASPA rs1057516962: Understanding Canavan Disease Carrier Status
The genetic variant rs1057516962 is located within the ASPA gene, which provides instructions for producing the enzyme aspartoacylase. This variant is associated with carrier status for Canavan disease, a rare, inherited neurological disorder that affects the brain's white matter.
What each genotype means
Canavan disease carrier status
This genotype indicates you are a carrier of a variant associated with Canavan disease, an autosomal recessive condition. Being a carrier typically means you are asymptomatic, but you should discuss this result with a genetic counselor or clinician to understand the implications for family planning.
This genotype is rare in the general population, though carrier frequencies vary significantly by ancestry.
Potential Canavan disease risk
This genotype indicates the presence of two copies of the variant. Because Canavan disease is an autosomal recessive condition, this result warrants clinical follow-up to confirm your health status and discuss potential implications with a medical professional.
This genotype is very rare in the general population.
What is rs1057516962 and Where is it Located?
The variant rs1057516962 is a single nucleotide polymorphism (SNP) situated on chromosome 17. It resides within the ASPA gene, a region of the genome responsible for encoding the enzyme aspartoacylase. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. While most SNPs have no effect on health, some are located in critical genes where they may alter the function of the resulting protein. Because this variant is linked to the ASPA gene, it is of interest to researchers studying inherited conditions that involve the metabolism of N-acetylaspartate (NAA) in the brain. Understanding the specific location of this variant helps scientists map how genetic changes can potentially disrupt normal biological processes.
The Role of the ASPA Gene
The ASPA gene is essential for the production of the enzyme aspartoacylase. This enzyme is primarily active in the brain, where it breaks down a substance called N-acetylaspartate (NAA). NAA is found in high concentrations in the brain, and its proper breakdown is necessary for the maintenance of myelin, the protective sheath that covers nerve fibers. When the ASPA gene contains pathogenic variants that significantly reduce or eliminate the activity of this enzyme, NAA can accumulate to toxic levels. This accumulation interferes with the health of myelin, leading to a condition known as spongy degeneration of the brain, or Canavan disease. The gene's function is therefore vital for normal neurological development and the long-term integrity of the central nervous system.
Research Associations and Evidence
Research into Canavan disease has identified numerous variants within the ASPA gene that can lead to the condition when inherited in an autosomal recessive pattern. This means an individual must typically inherit two copies of a pathogenic variant—one from each parent—to manifest the disease. The variant rs1057516962 is categorized in some databases as being associated with carrier status. Being a carrier means an individual has one copy of a variant that could potentially cause disease if paired with another pathogenic variant, but the carrier themselves does not typically show symptoms. The evidence strength for specific rare variants can be moderate, as clinical data is often limited to specific families or small cohorts. It is important to note that not all variants in the ASPA gene have the same impact, and clinical interpretation requires professional genetic counseling.
Population Frequency
Canavan disease is known to have a higher carrier frequency in certain populations, particularly among individuals of Ashkenazi Jewish descent, where carrier rates have been estimated at approximately 1 in 40. However, the variant rs1057516962 is considered rare in the general population. Because comprehensive population-wide screening for every possible ASPA variant is not universal, the exact frequency of this specific SNP across all global ancestries remains difficult to pinpoint precisely. Many rare variants are often under-represented in large-scale genomic databases, meaning that the absence of this variant in a specific population does not necessarily mean it is absent from that group entirely. Genetic diversity means that rare variants can appear in any ethnic or ancestral background.
What You Can and Cannot Do With This Information
Information regarding carrier status for rare genetic conditions is intended for educational purposes and should not be used for self-diagnosis. If you have received results indicating you are a carrier for an ASPA variant, this does not mean you have Canavan disease. However, it may be relevant for family planning, as carriers have a 25% chance of having an affected child if their partner is also a carrier of a pathogenic ASPA variant. You cannot use this information to predict the severity of a condition or to make medical decisions without professional guidance. If you are concerned about your carrier status, the most appropriate step is to consult with a certified genetic counselor or a medical geneticist. They can provide context based on your full genetic profile and family history, and help you understand the implications of your results.
How common is this variant?
The variant rs1057516962 is considered rare in the general population, though specific ASPA variants are more common in certain ancestral groups like the Ashkenazi Jewish population.
Frequently asked questions
What is Canavan disease?
Canavan disease is a rare, inherited neurological disorder that causes the progressive breakdown of nerve cells in the brain. It is caused by mutations in the ASPA gene, which leads to the accumulation of N-acetylaspartate.
Does being a carrier mean I have the disease?
No, being a carrier of a recessive condition like Canavan disease typically means you have one copy of a variant but do not show symptoms. Carriers are generally healthy but can pass the variant to their children.
Should I get tested for Canavan disease?
Carrier screening is often recommended for individuals with a family history of Canavan disease or those from populations with a higher known carrier frequency. You should discuss the necessity of testing with a healthcare provider or genetic counselor.
Is there a cure for Canavan disease?
Currently, there is no cure for Canavan disease, and treatment is primarily supportive. However, research into gene therapies and other clinical interventions is ongoing.
Sources & further reading
Educational information only, last refreshed 10/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1057516962?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ASPA
This variant is identified as a carrier mutation for Canavan disease.
Pathogenic missense variant (p.Glu285Ala / E285A) causing aspartoacylase deficiency and carrier status for autosomal recessive Canavan disease.
This variant is identified as a carrier mutation for Canavan disease, a rare neurodegenerative disorder.
Common pathogenic nonsense mutation (p.Tyr231Ter / p.Y231X) in ASPA underlying Canavan disease.
Severe pathogenic ASPA nonsense mutation (p.Tyr231Ter) responsible for Canavan disease in reproductive carrier screening.
Pathogenic ASPA missense variant (p.Glu285Ala) causing aspartoacylase deficiency (Canavan disease), standardly tested in preconception carrier panels.